Recombinant Human PTK7/CCK4 Fc Chimera Protein, CF

R&D Systems, part of Bio-Techne | Catalog # 9799-TK

R&D Systems, part of Bio-Techne
Catalog #
Availability
Size / Price
Qty
9799-TK-050
Print Quote
Bulk Order
100% Guarantee

Key Product Details

Source

HEK293

Accession #

Q13308-1

Structure / Form

Disulfide-linked homodimer

Conjugate

Unconjugated

Applications

Bioactivity

View all PTK7/CCK4 Proteins and Enzymes »

Product Specifications

Source

Human embryonic kidney cell, HEK293-derived human PTK7/CCK4 protein
Human PTK7/CCK4
(Met1-Thr704)
Accession # Q13308-1		 IEGRMD Human IgG1
(Pro100-Lys330)
N-terminus C-terminus

Purity

>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.

Endotoxin Level

<0.10 EU per 1 μg of the protein by the LAL method.

N-terminal Sequence Analysis

Ala31

Predicted Molecular Mass

101 kDa

SDS-PAGE

111-129 kDa, reducing conditions

Activity

Measured by its binding ability in a functional ELISA.
In a 100 µL reaction mixture containing biotinylated Recombinant Mouse Wnt-3a (Catalog # BT1324) at 50 ng/mL and Recombinant Human PTK7/CCK4 Chimera dilutions, the concentration of Recombinant Human PTK7/CCK4 Fc Chimera that produces 50% of the maximal binding response is 4-20 μg/mL.

Scientific Data Images for Recombinant Human PTK7/CCK4 Fc Chimera Protein, CF

Recombinant Human PTK7/CCK4 Fc Chimera Protein Binding Activity

Recombinant Human PTK7/CCK4 Fc Chimera Protein Binding Activity

Recombinant Human PTK7/CCK4 Fc Chimera (Catalog # 9799-TK) binds to Recombinant Biotinylated Mouse Wnt-3a (Catalog # BT1324) with an ED50 of 4-20 µg/mL.

Formulation, Preparation and Storage

9799-TK
Formulation Lyophilized from a 0.2 μm filtered solution in PBS.
Reconstitution
Reconstitute at 500 μg/mL in PBS.

Reconstitution Buffer Available:
Size / Price
Qty
Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: PTK7/CCK4

Protein tyrosine kinase 7 (PTK7), also known as colon carcinoma kinase 4 (CCK4), is a member of the receptor tyrosine kinase superfamily (1, 2). Human PTK7 is a 1040 amino acid (aa) glycoprotein containing a 674 aa extracellular domain (ECD), a 21 aa transmembrane domain, and a 345 aa cytoplasmic tyrosine kinase homology domain. Due to the lack of the residues required for catalytic activity in the kinase domain, PTK7 is considered a pseudokinase (1, 3). The mature ECD of PTK7 contains 7 Ig-like C2 type loops and shares 92% and 91% aa identity with mouse and rat PTK7 ECD, respectively (1-4). PTK7 is expressed in a wide array of tissue types ranging from lung and liver to kidney and placenta, and has been linked to a broad range of functions (5). While originally identified as being over-expressed in colon carcinomas, PTK7 has been shown to play a role in embryogenesis, epithelial tissue organization, angiogenesis, cell motility, and survival (1, 6, 7). PTK7 has been shown to be an important regulator of the Wnt signaling pathways, both canonical and non-canonical, and is linked to the regulation of the planar cell polarity pathway (3, 6). Soluble forms of PTK7 are known to be shed from the cell surface by matrix metalloproteinases (MMPs), a disintegrin domain and metalloproteinases (ADAMs), and gamma-secretase (3, 6). The soluble form is a co-receptor for the Semaphorin/Plexin and VEGF signaling pathways (8). Deregulation of PTK7 signaling has now been observed in numerous cancers including colon, gastric, lung, and acute myeloid leukemia (1, 3). Recent studies have shown that PTK7 expression promoted increased migration and resistance to apoptosis in leukemic cells and acute myeloid leukemia (AML) blasts, while knock-down of PTK7 induced apoptosis in colorectal carcinoma cells (2, 7). Further, other studies have suggested that the ratio of full-length vs. cleaved protein, not just expression, contributes to PTK7's metastatic effects in cancer (6).

References

  1. Shin, W. et al. (2008) Biochem. Bioph. Res. Co. 371:793.
  2. Meng, L. et al. (2010) PLoS ONE 5:e14018.
  3. Golubkov, V. et al. (2010) J. Biol. Chem. 285:35740.
  4. Berger, H. et al. (2017) Front. Cell Dev. Biol. 5:doi:10.3389/fcell.2017.00031.
  5. Park, S. et al. (1996) J. Biochem. 119:235.
  6. Golubkov, V. et al. (2014) J. Biol. Chem. 289:24238.
  7. Prebet, T. et al. (2010) Blood. 116:2315.
  8. Peradziryi, H. et al. (2012) Arch. Biochem. Biophys. 524:71.

Long Name

Protein Tyrosine Kinase 7

Alternate Names

CCK4

Entrez Gene IDs

5754 (Human); 71461 (Mouse); 301242 (Rat)

Gene Symbol

PTK7

UniProt

Q13308-1

Additional PTK7/CCK4 Products

Product Documents for Recombinant Human PTK7/CCK4 Fc Chimera Protein, CF

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Note: Certificate of Analysis not available for kit components.

Download SDS

Product Specific Notices for Recombinant Human PTK7/CCK4 Fc Chimera Protein, CF

For research use only

Privacy and Cookie Policy
Site Map
© Copyright 2024 Bio-Techne. All Rights Reserved.